Navigation Links
Merrimack Pharmaceuticals to Present at the 2010 Stifel Nicolaus Healthcare Conference
Date:9/13/2010

CAMBRIDGE, Mass., Sept. 13 /PRNewswire/ -- Merrimack Pharmaceuticals today announced that it will present at the Stifel Nicolaus 2010 Healthcare Conference in Boston. William Sullivan, Vice President of Finance, will provide a company overview at 11:30am, EDT, Friday, September 17, 2010 at the Four Seasons Hotel in Boston, Massachusetts.

(Logo: http://photos.prnewswire.com/prnh/20100913/NE63515LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100913/NE63515LOGO)

About MerrimackMerrimack Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and development of novel medicines for the treatment of cancer and inflammation. The Company is advancing a robust pipeline of engineered therapeutics paired with molecular diagnostics. Merrimack has three oncology candidates in clinical development: MM-121, partnered with sanofi-aventis, in Phase 2 clinical testing, MM-111 in Phase 1/2 clinical testing, MM-398, partnered with PharmaEngine, Inc., in Phase 2 clinical testing and multiple pre-clinical development and research stage programs in the pipeline. MM-121, MM-111, and MM-398 are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The Company's proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, integrates the fields of engineering, biology and computing to enable mechanism-based model driven discovery and development of both therapeutics and diagnostics. Merrimack is a privately-held company based in Cambridge, Massachusetts. For additional information, please visit http://www.merrimackpharma.com. ContactsKathleen Petrozzelli, Corporate Communications, 617-441-1043, kpetrozzelli@merrimackpharma.com, http://www.merrimackpharma.com Betsy Raymond Stevenson, RaymondStevenson Healthcare Comms, 860-984-1424, betsy@raymondstevenson.com
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
2. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2017)... , May 15, 2017  Amy Baxter MD, ... industry leader in noninvasive pain relief, was awarded a ... magazine. Baxter was recognized at the MM&M Top ... New York City on May 10, 2017. ... the biopharma industry go "beyond the pill."  ...
(Date:5/12/2017)... , May 12, 2017  The China and Canada ... technology that consumes less water, energy and detergent, and features a ... product LaughingU, a shoebox-sized washing machine that washes and sanitizes women,s ... ... LaughingU, is compact, and does not require an external water inlet. ...
(Date:5/10/2017)... -- Hologic, Inc. (Nasdaq: HOLX ) announced ... quarter ended April 1, 2017 .   GAAP diluted ... to the prior year period as the sale of ... while non-GAAP diluted EPS of $0.50 increased 6.4%.  Revenue ... currency terms.  Excluding the effects of blood screening and ...
Breaking Medicine Technology:
(Date:5/22/2017)... IL (PRWEB) , ... May 22, 2017 , ... ... is part of a larger group investing in InsightRX, an early stage company ... patient’s underlying biological and pharmacological characteristics. Greatpoint Ventures Innovation Fund acted ...
(Date:5/21/2017)... , ... May 20, 2017 , ... ... systems between ABC Financial Services and financial systems. , Dozens of ... exported files that are electronically processed through GetLinked into their club’s accounting system ...
(Date:5/21/2017)... , ... May 21, 2017 , ... ... has brought together a cross-disciplinary group of scholars, policymakers, and activists wanting to ... Justice, and Equity is the third book from a recent series of ...
(Date:5/21/2017)... ... ... Following the tragic and widely publicized death of Rory Staunton, 12, from undiagnosed ... a protocol to quickly identify and treat the condition. , The mandate led ... saved Rory or anyone else’s life. , Now, five years after the boy’s ...
(Date:5/19/2017)... ... May 19, 2017 , ... A ... University of Charlotte recently began recruitment efforts for the inaugural cohort of its ... the skills, knowledge and expertise to approach and address the unique nuances healthcare ...
Breaking Medicine News(10 mins):